News - Astellas Pharma, Neurological


Popular Filters

Kyowa Hakko and Astellas get new indication for Pasetocin and Sawacillin; latter applies for new Dormicum use


Japanese drug major Kyowa Hakko Kirin (TYO: 4151) and Astellas Pharma (TYO: 4503) have jointly announced…

Asia-PacificAstellas PharmaDormicumGastro-intestinalsKyowa Hakko KirinNeurologicalPasetocinPharmaceuticalRegulationSawacillin

Regulatory briefs from Astellas, Janssen, Biogen and Elan, and QRxPharma


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says the US Food and Drug Administration…

Anti-viralsAstellas PharmaBiogen IdecBiotechnologyElanEuropeJanssenJohnson & JohnsonMoxDuoNeurologicalNorth AmericaOncologyPharmaceuticalPrezistaQRxPharmaRegulationTarcevaTysabri

Astellas launches RLS drug Regnite in Japan


Japanese drug major Astellas Pharma (TOY: 4503) says that Regnite (gabapentin enacarbil) extended-release…

Asia-PacificAstellas PharmaMarkets & MarketingNeurologicalPharmaceuticalRegniteXenoPort

Astellas pulls EU application to extend use of Qutenza


The European Medicines Agency has been formally notified by Astellas Pharma Europe, a subsidiary of Japanese…

Astellas PharmaEuropeNeurologicalPharmaceuticalQutenzaRegulation

Japanese approval for Regnite and Ranmark


Japanese drug major Astellas Pharma (TYO: 4503) and USA-based XenoPort (Nasdaq: XNPT) revealed yesterday…

AmgenAsia-PacificAstellas PharmaAstraZenecaBiotechnologyDaiichi SankyodenosumabFinancialNeurologicalOncologyPharmaceuticalRanmarkRegniteRegulationXenoPort

Despite generics for two key drugs, neuropathic pain market will grow to $8.4 billion in 2020


The neuropathic pain drug market will experience modest growth over the next decade, increasing from…

Astellas PharmaEli LillyJohnson & JohnsonMarkets & MarketingNeurologicalPfizerPharmaceutical

Back to top